Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nexentis Technologies Inc's Business Segments
Nexentis Technologies Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Nexentis Technologies Inc
Nexentis Technologies Inc., incorporated in Delaware in 2009 and later reincorporated in Nevada, operates primarily through its wholly-owned Israeli subsidiary, MitoCareX Bio Ltd., and one joint venture. The company focuses on sustainable operations in sectors including solar projects and oncology biotechnology. MitoCareX Bio Ltd. is a drug discovery company developing therapeutics targeting the mitochondrial carrier family (SLC25A protein family), with a focus on one specific, undisclosed SLC25A protein. Its core technology integrates structural biology and computational chemistry, enabling a platform approach applicable to all 53 members of the SLC25A family. MitoCareX’s current therapeutic targets include Non-Small Cell Lung Cancer (NSCLC) and pancreatic cancer, with additional evaluation of compounds for inflammatory metabolic diseases. Previously, Nexentis owned Save Foods Ltd., which developed sanitizing solutions for the water and food industry, particularly in the potato-growing sector; Nexentis transferred its shares in Save Foods to Voice Assist, Inc. in 2026. Nexentis continues to provide advisory and support services to Voice Assist under a Services Agreement. The company’s operations and strategic activities encompass oncology biotechnology and sustainable technologies.
As of December 31, 2024, the Company reported two segments: (i) Pathogen prevention and shelf life extension, comprising Save Food Ltd., and (ii) N2O emissions global warming solutions, comprising NTWO OFF Ltd. In April 2025, the Company sold NTWO OFF Ltd., classifying this segment as discontinued operations. Save Food Ltd. was also classified as discontinued operations as of December 31, 2025, due to a planned sale. Following these changes and the acquisition of MitoCareX in October 2025, the Company reassessed its segments. As of December 31, 2025, the Company reported two segments: (i) Biotechnology activity, consisting of MitoCareX from the acquisition date, and (ii) Renewable energy projects, consisting of NITO Renewable Energy, Inc. and a solar photovoltaic joint venture project. The Chief Operating Decision Maker evaluates performance and allocates resources primarily based on segment operating loss. Prior period segment information has been recast to conform to the current presentation.